FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Axon Enterprise, Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We decrease our 12-month target price by $92 to $693, or 65.0x our 2027 EPS estimate, a discount relative to AXON's average forward P/E of 92.7x (during the trailing-12-month period). We trim our EPS estimates for 2026 by $0.16 to $7.78 and 2027's by $0.12 to $10.66. AXON's fundamental strength remains compelling as the company extends its competitive moat through an integrated ecosystem that combines hardware, cloud software, and AI capabilities. With 30%+ revenue growth for nine consecutive quarters, AXON is capitalizing on a $159 billion TAM while penetrating less than 15% of its core U.S. market. Multiple growth drivers are accelerating simultaneously: AI Era Plan bookings surged 140% Y/Y with near-universal adoption among large agencies; Dedrone counter-drone revenue jumped 300% Y/Y; and international revenue doubled, reaching 20% of total sales. Axon's 125% net revenue retention and $14.3 billion in future contracted bookings (+44% Y/Y) underscore strong visibility.

Related Articles

Asia

Apollo Micro Systems Clinches Orders Worth INR510 Million; Shares Up 4%

Defense manufacturer Apollo Micro Systems (NSE:APOLLO, BOM:540879) has secured new orders worth a total of 510.3 million Indian rupees, according to a Friday filing to the Indian stock exchanges.Of the total, orders of 174.8 million rupees from the Ministry of Defence, Government of India, contracts of 95.3 million rupees from public sector defense undertakings, and orders worth 240.2 million rupees from private companies.The company's shares were up nearly 4% in recent trade.

$BOM:540879$NSE:APOLLO
Asia

PKU HealthCare Gets Nod for Tofacitinib Citrate's Marketing

PKU HealthCare (SHE:000788) obtained approval from China's National Medical Products Administration for the marketing of Tofacitinib Citrate, according to a Shenzhen bourse filing on Friday.The drug is a potent Janus kinase (JAK) inhibitor, primarily used for patients suffering from chronic autoimmune conditions, including ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis.The healthcare company's share rose 1% during the afternoon trade.

$SHE:000788
Asia

Toyota Expects Lower Fiscal 2027 Profit Amid Tariff, Cost Pressures

Toyota Motor (TYO:7203) forecasts weaker profit for fiscal 2027 as rising material and energy costs linked to Middle East tensions are expected to weigh on earnings, according to a Friday filing on the Tokyo Stock Exchange.The automaker expects net income attributable to shareholders to decline 22% to 3 trillion yen in the year ending March 2027, with basic earnings per share projected at 251.25 yen. Revenue is expected to rise slightly to 51 trillion yen.For the fiscal year ended March 2026, Toyota reported net profit attributable to shareholders of 3.848 trillion yen, down 19% from a year earlier, while revenue rose 5.5% to 50.7 trillion yen. Earnings per share fell to 295.25 yen from 359.56 yen a year earlier.The company raised its annual dividend to 95 yen per share from 90 yen and forecast a payout of 100 yen for fiscal 2027.

$TYO:7203